Polpharma Biologics Group Announces That Its Joint Venture Bioeq Has Submitted a Biologics License Application (BLA) for Biosimilar Ranibizumab to the U.S. Food and Drug Administration (FDA)
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®).
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) used to treat various types of macular-degenerative diseases such as neovascular (wet) age-related macular degeneration, diabetic retinopathy, macular edemas and myopic choroidal neovascularization. Worldwide, at least 25 to 30 million people are affected by age-related macular degeneration. The launch of a biosimilar Ranibizumab can increase market competition, reduce cost and expand patient access with proven analytical and clinical similarity to the original product. It works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.
Subject to FDA's approval of this BLA, the product will be exclusively commercialized by Coherus BioSciences, Inc. in the United States.
Said submission represents the most recent milestone for Bioeq's ranibizumab biosimilar program and compliments marketing authorization applications submitted to EMA and UK MHRA already in July this year.
Dr Joerg Windisch, CEO of the Polpharma Biologics Group, commented:
“The submission of a BLA to the FDA is a major milestone for any therapeutic and brings hope to patients across the US. This announcement carries a tangible promise of treatment choice and improved access to those who suffer from debilitating vision loss, including age-related macular degeneration. This is another representation of our commitment to providing safe and effective medicines to patients.”
1) Lucentis ® is a registered trademark of Genentech Inc.
About Ranibizumab biosimilar
The Ranibizumab biosimilar, previously designated as FYB201 (and also known as CHS-201), has been originally licensed from Formycon AG (FRA: FYB/ WKN A1EWVY), a leading German biosimilars company, and subsequently developed by Bioeq AG, a joint venture between Polpharma Biologics and Santo Holding AG (Strüngmann Group). Phase III clinical trials for FYB201 have clinically demonstrated that the efficacy of FYB201 in patients with nAMD is comparable to that of Lucentis®.
About biosimilars
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Biosimilars exhibit proven analytical and clinical similarity to their respective branded reference products.
About Polpharma Biologics Group
The Polpharma Biologics Group creates quality biosimilars with a passion to improve lives of patients. The group has built an extensive and growing pipeline of biosimilars to treat a number of medical conditions across major therapeutic areas. Several of these biosimilar assets have already been commercially partnered with the world’s largest biopharmaceutical companies.
The group operates a network of state-of-the-art development and manufacturing facilities across Europe, actively investing in technology, people and know-how, employing over 800 specialists from around the globe.
Learn more at www.polpharmabiologics.com
About Bioeq
Bioeq is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses and commercializes biosimilars.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210806005187/en/
Contact information
Joseph Reeds
Head of Marketing, Polpharma Biologics
Joseph.reeds@polpharmabiologics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Jumpmind Announces Strategic Investment from Lone View Capital15.9.2025 13:00:00 EEST | Press release
Jumpmind, a leading provider of innovative retail technology solutions, announced today that Lone View Capital (“Lone View”), a growth-oriented private equity firm focused on technology and software investments, has made a strategic investment, acquiring a controlling stake in the company. Founded in 2008, Jumpmind was recently recognized as a Leader in the Forrester Wave™ for Point of Service Solutions (Q4 2024). The company’s flagship product, Jumpmind Commerce, is a cloud-native, microservices-based point of service platform that enables retailers to unify digital and in-store experiences, streamline checkout, and deliver more personalized customer interactions. Trusted by leading retailers worldwide, the platform supports device independence, rapid deployment, and highly configurable customer journeys – empowering enterprises to adapt quickly in today’s dynamic retail landscape. Jumpmind was named POS Solution of the Year in the 2025 RetailTech Breakthrough Awards. In addition to i
Ookla Launches Speedtest Certified™ to Provide Definitive Network Verification for Properties15.9.2025 13:00:00 EEST | Press release
Ookla®, a global leader in connectivity intelligence, today announced the launch of Speedtest Certified™, the definitive network connectivity verification program for properties. Leveraging Speedtest®'s globally trusted testing methodology and unrivaled brand recognition, the program answers an increasingly important question: how can property owners prove to consumers that they deliver superior connectivity and are ready to support today's connectivity needs? This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915248087/en/ Pictured is the official plaque awarded to locations that achieve Speedtest Certified™ status, signifying they have met rigorous standards for outstanding network performance. In an era where reliable internet is non-negotiable for tenants, guests, and employees, the stakes for businesses are high – poor connectivity can impact both the bottom line and customer satisfaction. Speedtest Certified addresses t
The AgreenaCarbon Project Becomes the First Large-Scale Soil Carbon Project to Achieve Verra Verification, Now Issuing 2.3 Million Verified Carbon Credits15.9.2025 11:30:00 EEST | Press release
Agreena, the company powering the global transition to regenerative agriculture, has achieved verification of its AgreenaCarbon Project under Verra’s Verified Carbon Standard (VCS) Program’s VM0042 Improved Agricultural Land Management v2.0 methodology – the first large-scale arable agriculture project to do so. By passing this milestone, Agreena is now issuing 2.3 million Verra-verified carbon credits that are not only readily available, but deliver immediate, measurable climate impact. This follows the project’s successful validation in January 2025. While validation confirms that the project design and methodology meet the requirements of Verra’s VCS Program, verification is the critical next step - confirming, through independent assessment, that the project has delivered measurable climate outcomes as intended. Verra’s VCS Program is the world’s most widely recognised greenhouse gas crediting standard and is approved by the Integrity Council for the Voluntary Carbon Market. Unlike
Libertex Voted “Best CFD Broker - Europe” at Global Forex Awards15.9.2025 11:23:00 EEST | Press release
Multi-awarded online broker Libertex adds another accolade in its trophy case as it has been named Europe's Best CFD Broker by Global Forex Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915045703/en/ (Photo: Libertex) This title not only highlights the broker’s role as a trusted leader, but it also reflects Libertex’s commitment to delivering excellence on all levels. Applying to an exhaustive set of the company’s services, from client support to trading technology, education, and asset coverage, the accolade bolsters the broker’s position in the global CFD trading arena while shining a spotlight on its continuous efforts to stay relevant. Speaking about the recent win, Libertex Group CMO Marios Chailis said: “We are truly honoured to be recognised as ‘Best CFD Broker - Europe’ at the Global Forex Awards. This award reflects not only the efforts of our dedicated team but also the confidence our clients place in u
Hanshow and Delfi Partner to Expand Digital Solutions in Europe15.9.2025 11:04:00 EEST | Press release
Hanshow, a global leader in Electronic Shelf Labels (ESLs) and digital retail solutions, and Delfi Technologies, a Danish retail technology pioneer with decades of expertise in ESL platforms, today announced a new partnership, marking the start of closer cooperation to expand ESL offerings for retailers across Europe and accelerate the next phase of in-store digital transformation. Through this partnership, Delfi Technologies’ Breece System platform will be strengthened with Hanshow’s world-class ESL portfolio, proven in thousands of deployments worldwide. This partnership combines Delfi’s experience with ESL deployments in Europe and Hanshow’s global innovation leadership. Together, Hanshow will bring more flexibility, more options, and more value to retailers, helping them accelerate their digital transformation with lower costs and greater impact. The partnership also reinforces both companies’ commitment to sustainability. By replacing paper-based processes with digital price manag
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom